A man with neurofibromas who didn't know he's been clinically diagnosed with NF1, learns he harbors a deeply intronic, likely ...

The company says the system can benefit pharmaceutical and biotech firms seeking rapid feedback on drug candidates or genome editing.

Using the iconPCR system, n6 presents enhancements in low-pass whole genome sequencing. This approach enables balanced, ...

Europe’s leading cancer conference may be swimming in antibody-drug conjugate data, but AstraZeneca remains convinced that its in-house pipeline sets the pharma apart. The U.K.-based drugmaker earned ...